Navigation Links
New target for anti-flu drug development
Date:9/22/2007

Boston, August 15, 2007---Scientists at Cure Lab, Inc., a biotechnology company based in Canton, Massachusetts, in collaboration with researchers at Boston University and Harvard Medical School have discovered a potential new target for the development of anti-influenza (flu) drugs, including those that may be effective against potentially pandemic influenza strains like H5N1.

Their findings have been published in the August 15, 2007 issue of the journal Cell Cycle.

The potential drug target is the flu protein M2, long known to be highly conserved between avian and human strains of the virus. Scientists at Cure Lab found that this M2 protein may single-handedly kill human cells.

This effect may constitute a previously unknown mechanism of influenza virus pathogenicity said Dr. Alex Shneider, senior author on the paper and CEO of the company. If so, drugs that are shown to prevent M2-dependent cell killing have the potential to be used for the treatment of flu.

Membranes covering human and avian cells do not allow ions to move in and out of the cell freely, thus maintaining internal homeostasis. M2 protein of flu virus forms ion channels allowing ion trafficking into cells that cells no longer control. Dr. Shneider and his group not only demonstrated that M2 kills mammalian cells, but also showed that ion channeling through M2 pores may be a molecular mechanism of this cell killing process. Dr. Shneider said that Developing drugs which block M2 ion channels could reduce or eliminate M2-induced cell death, and thus may be a new strategy for targeted development of anti-influenza drugs.

In collaboration with Dr. Vladimir L. Gabai from Boston University, and Dr. Shamil R. Sunyaev from Harvard Medical School scientist from Cure Lab, Inc. have developed mutant forms of M2 protein, where the ion channel is blocked. The researchers have shown that these specific mutations they introduced in the protein significantly reduces its ability to kill the cell. From the point of view of the pharmaceutical industry and feasibility studies, introducing mutations into a protein, which mimic an effect of a future drug, is a way to validate the feasibility of a drug target.

Dr. Shneider said that an M2-targeted search for new anti-influenza drugs could lead to a new generation of medicines which will complement those currently used for influenza disease prevention and treatment. Dr. Petr Ilyinskii, a principal scientist at Cure Lab and the first author on the paper also pointed out that This is especially important since an increasing number of influenza strains are becoming resistant to the drugs that are now widely used.


'/>"/>

Contact: Alex Shneider
thoidis@curelab.com
609-841-1201
Cure Lab, Inc.
Source:Eurekalert

Related biology technology :

1. Enhanced Amplification of Long Targets with PfuTurbo DNA Polymerase
2. Microarray Target Purification Kit and the Microarray Target Synthesis Kit (T7)
3. Gene Expression Arrays: Highly Sensitive Detection of Expression Patterns with Improved Tools for Target Amplification
4. Detection of antibody-stained cell surface and intracellular protein targets with the Agilent 2100 bioanalyzer
5. Protect RNA and Improve Target Cell Identification
6. Feasibility of Multiplexing Bio-Plex Total Target and Phosphoprotein Assays
7. Development of Radioligand Binding Assays for the Motilin Receptor Using ScreenReady Targets.
8. Calcium Plus Assay Kit, Superior Detection for Specialized Targets
9. ESR1 Gene Expression in Oncology and Metabolic Diseases Using the ASCENTATM System Target Validation and Identification of Novel Disease Indications
10. A Screen of shRNAs Targeting Tumor Suppressor Genes to Identify Factors Involved in Paclitaxel Sensitivity
11. TomoTherapy revises IPO money target
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/21/2017)... -- Bioptix, Inc. (Nasdaq: BIOP ... 14, 2017 the Board of Directors of the Company ... certain employees associated with the September 2016 acquisition of ... on January 16, 2017 and terminations are expected to ... severance benefits in certain circumstances of up to one ...
(Date:1/20/2017)... ... January 20, 2017 , ... The two newest companies to join the ... Vironika, a spin out from The Wistar Institute, and Sanguis, launched by a trio ... Market Street. , Vironika is developing a treatment for a chronic viral infection ...
(Date:1/20/2017)... NEW YORK , January 20, 2017 ... Health Organization, cancer is one of leading causes of ... in 2012. Although the number of cancer related deaths ... since 1990. Rising in incidence rate of various cancers ... According to a research report by Global Market Insights, ...
(Date:1/19/2017)... 19, 2017  Market Research Future has a half cooked research ... Biopsy is growing rapidly and expected to reach USD 450 Million ... ... Biopsy Market has been assessed as a swiftly growing market and ... in the coming future. There has been a tremendous growth in ...
Breaking Biology Technology:
(Date:1/12/2017)... 2017  Trovagene, Inc. (NASDAQ: TROV ), ... announced that it has signed agreements with seven strategic ... Middle East for commercialization of ... first wave of international distribution agreements for Trovagene,s CLIA ... The initial partners will introduce Trovagene,s liquid ...
(Date:1/6/2017)... 2017  Privately-held CalciMedica, Inc., announced that it ... of a novel calcium release-activated calcium (CRAC) channel ... Acute pancreatitis, sudden painful inflammation of ... can be very serious.  In severe cases it can ... hospital stays, time in the ICU and substantial ...
(Date:1/3/2017)... , Jan. 3, 2017 Onitor, provider of ... of Onitor Track, an innovative biometric data-driven program designed ... this month at the 2017 Consumer Electronics Show (CES) ... In the U.S., the World Health Organization (WHO), ... two-thirds of adults who are overweight or obese. WHO ...
Breaking Biology News(10 mins):